Participated · Series B · Aug 2024

NeuroTherapia, led by President and CEO Tony Giordano and based in Cleveland, OH, is a clinical-stage biotech developing oral, small-molecule drugs to address neuro-inflammatory CNS conditions including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Its lead program, NTRX-07, is an orally available cannabinoid receptor agonist intended to inhibit microglia-mediated inflammation without affecting clearance of toxic beta amyloid. The company says its therapeutics aim to inhibit proteins expressed by microglia that drive CNS inflammation while preserving amyloid clearance. NeuroTherapia raised $12.3M in a Series B financing and intends to use the proceeds for continued clinical development of NTRX-07. The company plans a second close in six months to raise additional funds to enable development of a recently discovered second-generation molecule for a separate indication driven by neuroinflammation. No operating metrics (revenue/users) were disclosed in the article. NeuroTherapia is an early-stage clinical pharmaceutical company developing NTRX-07, a first-in-class drug candidate for Alzheimer’s disease. The company announced it has received a grant from the Alzheimer’s Association Part the Cloud program to support development of NTRX-07. NTRX-07 is being developed as a treatment for Alzheimer’s disease. The grant provides funding to advance the program through development. As an early-stage clinical firm, NeuroTherapia's near-term plans center on progressing NTRX-07. The company issued the announcement in a press release from NeuroTherapia, Inc. NeuroTherapia is a Cleveland, OH-based clinical-stage company developing NTRX-07, an orally available cannabinoid receptor agonist aimed at treating neuroinflammation implicated in neurodegenerative diseases. The company is completing its first-in-human clinical trial of NTRX-07, with part of the trial funded by an Alzheimer’s Association grant. It closed an $8.8M Series A to finish the first-in-human work and to undertake additional preclinical studies. The planned preclinical studies are intended to support subsequent clinical trials by demonstrating safety following longer-term administration and showing biological activity. Separately, NeuroTherapia received a $150,000 Technology Validation and Start-up Fund grant from Ohio Third Frontier to complete biodistribution research after radiolabeling the molecule. The company also strengthened its board with the addition of Karoly Nikolich, Ph.D., joining existing board members including the chairman Mr. Reher, President and CEO Tony Giordano, Ph.D., and Akhil Saklecha, M.D., from Cleveland Clinic.

Participated · Series B · Oct 2021

Chase Therapeutics, founded in 2016 and based in Washington, DC, focuses on rapid translation of neuroscience discoveries into therapies for central nervous system disorders. Its lead programs are CTC-413 for Parkinson’s disease and CTC-501 for Major Depressive Disorder, both entering Phase 3 development. The company is also developing a companion diagnostic intended to identify Parkinson’s patients earlier and more accurately. Clinical data cited by the company indicate CTC-501 is well-tolerated and provides rapid symptomatic relief in MDD, while CTC-413 showed encouraging proof-of-concept results with symptom mitigation and signs of neuroprotective potential. Chase plans to advance these programs and the diagnostic into pivotal trials supported by recent financing.

Participated · Series B · May 2014

Chase Pharmaceuticals is a US-based company developing novel approaches to improve treatments for Alzheimer’s disease; its lead candidate is CPC 201. CPC 201 is advancing through Phase 2a and Phase 2b clinical trials, and the company assembled financing to support those studies. A $21 million investor syndicate was put together to fund the Phase 2 trials. Named participants in that syndicate include Cipla (EU) Ltd, Edmond de Rothschild Investment Partners and New Rhein Healthcare LLC. Cipla initially invested $1.5 million in May 2014 for a 14.6% stake and has now made an additional $3 million investment, bringing its aggregate to approximately $5.12 million for a 16.7% fully diluted stake. Cipla had also committed to a further $4.5 million contingent on achievement of specified milestones. Original venture funding for Chase was provided by the Brain Trust Accelerator Fund in 2010. Chase Pharmaceuticals is an early-stage drug development company focused on Alzheimer’s disease, based in Washington, DC. Its lead product is CPC-201 (oral) and the company is also developing CPC-252 for transdermal administration. Chase says it uses a unique, patented approach intended to significantly improve the efficacy and safety of marketed Alzheimer’s drugs such as ARICEPT and Exelon. Proceeds from its most recent financing will fund Phase 2a and Phase 2b clinical trials of the lead product following Phase 1 studies. The company was founded in 2007 and previously received Series A funding in 2010 and 2011 from Brain Trust Accelerator Fund to support Phase I trials. The privately held company has added John M. Siebert as CEO and expanded its board with representatives from its new investors.